SBTi Registry
Explore 1 matching companies with public, verified Science Based Targets commitments.
Data sourced from the Science Based Targets initiative (SBTi).
Show
20
per page| Sector | Region | Near-Term Status | Size | ||||
|---|---|---|---|---|---|---|---|
| Astellas Pharma Inc. | Pharmaceuticals, Biotechnology and Life Sciences | Asia | Targets set | Large | 2 | Jan 19, 2023 | |
Near-Term Status Targets set Near-Term Classification 1.5°C Near-Term Target Year - Long-Term Status - Net-Zero Status - Net-Zero Year - Sector Pharmaceuticals, Biotechnology and Life Sciences Region Asia Organization Type Corporate Location Japan Company Size Large Target Statement Astellas Pharma Inc. commits to reduce absolute scope 1 and 2 GHG emissions 63% by FY2030 from a FY2015 base year. Astellas Pharma Inc. commits to reduce absolute scope 3 GHG emissions 37.5% by FY2030 from a FY2015 base year. Stakeholders Shingo Iino Vice President, Head of Sustainability SVP, Head of Global Procurement | |||||||
Show
20
per pageTurn Commitments Into Impact
Thousands of companies have set public Scope 3 emissions-reduction targetsthrough SBTi, but few have the tools to deliver on them. Carbon3 gives you the infrastructure to plan, track, and execute the supply-chain decarbonization work behind your commitment, turning a public pledge into measurable progress. See how it works.